Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.57 |
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20575398 | 0.99 | GAA (0.70) | GAASMN1; SMN2KDM4EALDH1A1HRH3 | |
| SCHEMBL1244065 | 0.93 | HRH3 (0.69) | GAASMN1; SMN2KDM4EALDH1A1HRH3 | |
| SCHEMBL991354 | 0.87 | ALDH1A1 (0.76) | GAASMN1; SMN2KDM4EALDH1A1HRH3 | |
| SCHEMBL5685572 | 0.87 | PSMB1 (0.75) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL3646371 | 0.86 | KDM4E (0.58) | GAASMN1; SMN2KDM4EALDH1A1NPC1 | |
| SCHEMBL4455251 | 0.86 | ALDH1A1 (0.92) | GAASMN1; SMN2KDM4EALDH1A1HRH3 | |
| Hydrochloric Acid SCHEMBL7887532 | 0.86 | ALDH1A1 (0.74) | GAASMN1; SMN2KDM4EALDH1A1HRH3 | |
| SCHEMBL3007594 | 0.86 | GAA (0.71) | GAASMN1; SMN2KDM4EALDH1A1HRH3 | |
| Hydrochloric Acid SCHEMBL6174512 | 0.85 | PSMB1 (0.73) | SMN1; SMN2KDM4EALDH1A1HRH3THRB | |
| SCHEMBL1358423 | 0.85 | PSMB1 (0.78) | KDM4EALDH1A1HRH3THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20230002394-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-115160257-A | Synthetic preparation method of curcumin derivative | 河南省锐达医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210214362-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2021-07-15 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-111253339-B | Synthetic preparation method of curcumin derivatives and application of curcumin derivatives in cancer treatment | 河南省锐达医药科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-20200407364-A1 | FUSED BICYCLIC COMPOUNDS | AKARNA THERAPEUTICS LTD (GB) | 2020-12-31 | — | — | US | disclosed |
| US-20200325140-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (CH) | 2020-10-15 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-1663953-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-6310070-B1 | FOR TREATING NEPHRITIS, IMPROVING PROTEINURIA DUE TO GLOMERULONEPHRITIS AND PREVENTING AGGRAVATION OF NEPHRITIS | JAPAN ENERGY CORPORATION (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-0999211-A1 | NOVEL PURINE DERIVATIVES AND MEDICINAL USE THEREOF | JAPAN ENERGY CORPORATION (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325140-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GAA 199/4885SMN1; SMN2 61/4885KDM4E 3393/4885 |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | GAA 210/4885SMN1; SMN2 3671/4885KDM4E 123/4885 |
| US-20230002394-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GAA 199/4885SMN1; SMN2 61/4885KDM4E 3393/4885 |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GAA 199/4885SMN1; SMN2 61/4885KDM4E 3393/4885 |
| US-20200407364-A1 | FUSED BICYCLIC COMPOUNDS | BICRA, PAICS, NDC1 | GAA 3157/4885SMN1; SMN2 1918/4885KDM4E 3546/4885 |
| US-20210214362-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GAA 199/4885SMN1; SMN2 61/4885KDM4E 3393/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GAA 199/4885SMN1; SMN2 61/4885KDM4E 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.